In children with cystic fibrosis, the initiation of elexacaftor-tezacaftor-ivacaftor therapy may alter the status of fat soluble vitamins and change how supplementation relates to their serum levels.

First-time lung transplants in patients with CF significantly decreased after ETI became available, while retransplants were largely unaffected.